We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+3.46%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.35B
AUM Growth
-$141M
Cap. Flow
+$107M
Cap. Flow %
3.2%
Top 10 Hldgs %
41.69%
Holding
77
New
11
Increased
22
Reduced
20
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$68M
2
APLS
Apellis Pharmaceuticals
APLS
+$67.9M
3
TGTX icon
TG Therapeutics
TGTX
+$45.8M
4
KRRO icon
Korro Bio
KRRO
+$42.6M
5
AXSM icon
Axsome Therapeutics
AXSM
+$40.6M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$108M
2
GERN icon
Geron
GERN
+$68.2M
3
APGE
Apogee Therapeutics
APGE
+$64.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
5
TRML
Tourmaline Bio
TRML
+$36.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
2 Miscellaneous 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
76
DELISTED
Tourmaline Bio
TRML
– –
-1,595,400
Closed -$36.5M
ITCI
77
PUT
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-175,400
Closed -$12.1M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Deep Track Capital held 77 positions worth $3.35B, down 4% from $3.49B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deep Track Capital deployed $107M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was TG Therapeutics: 2,870,131 shares worth $51.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Insmed, an estimated $108M trimmed.

  • Deep Track Capital's largest Q2 2024 buy was TG Therapeutics: 2,870,131 shares worth $51.1M.
  • Deep Track Capital added most to Immunovant in Q2 2024, an estimated $68M increase.
  • Deep Track Capital's biggest Q2 2024 reduction was Insmed, cutting an estimated $108M.
  • Deep Track Capital fully exited Tourmaline Bio in Q2 2024, selling an estimated $36.5M.
  • Deep Track Capital's ten largest holdings make up 42% of its $3.35B portfolio in Q2 2024.
  • Deep Track Capital opened 11 new positions and closed 9 in Q2 2024.
  • Deep Track Capital's portfolio value fell 4% quarter-over-quarter to $3.35B.

Based on Deep Track Capital's 13F filing for Q2 2024, filed 14 Aug 2024.